Led by a proven management team, TESARO has in-licensed and is developing several promising drug candidates, including rolapitant and niraparib. Rolapitant is a potent selective neurokinin-1 receptor antagonist that has commenced Phase 3 clinical testing for the prevention of chemotherapy induced nausea and vomiting. Niraparib is an orally active and potent PARP inhibitor that will commence Phase 3 pivotal trials in both the ovarian and breast cancer settings.

TESARO was co-founded by former executives of MGI Pharma (acquired by Eisai Co., Ltd. for $3.9 billion) and Abraxis BioScience (acquired by Celgene for $2.9 billion). TESARO became a public company in 2012, raising $81 million.